

IN THE SPECIFICATION:

Please amend the specification as follows: Page 1, line 2, please insert -- This is a Divisional Application of allowed United States Patent Application No. 09/224,014, which is a Continuing Application of PCT/GB97/02857, filed October 17, 1997 and claiming priority to Great Britain Patent Application No. 9621680.9, filed October 17, 1996, and Great Britain Patent Application No. 9624457.9, filed November 25, 1996. --

Immediately after page 18 and before the first page of claims (page 19), if appropriate, please insert the enclosed pages identified as -- Sequence Listing --.

Please accept the enclosed printed version of the sequence listing, which is identical to the sequence listing submitted for parent application USSN 09/238,356, and the required Statements under 37 C.F.R. §1.821 (f) and (g) (below).

REMARKS

It is submitted that the claims herewith and the claims as originally presented are and were in full compliance with the requirements of 35 U.S.C. §§101, 102, 103 and 112. The addition and amendment of the claims herein are not made for the purpose of patentability within the meaning of 35 U.S.C. §§ 101, 102, 103 or 112; but rather the addition and amendment of the claims are made simply for clarification and to round out the scope of protection to which Applicants are entitled. Support for the amendments is found throughout the specification and from the originally-filed claims; no new matter is added.

This amendment is made to provide a lineage, including proper reference to the U.S. application of which this is a divisional application.

The Examiner's attention is respectfully drawn to the fact that the sequence listing in this application is identical to that of predecessor parent application U.S. Serial No. 09/224,014 filed June 26, 2001. It is respectfully requested that the U.S. PTO use the electronic version of the sequence listing in that prior application, making any necessary changes therein for this application, e.g., as to Serial Number and filing date.

It is believed that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below. Pursuant to 37 C.F.R. §1.821(f), the undersigned attorney hereby states that the content of the paper copy submitted herewith, and the computer readable copy of the Sequence listing submitted in U.S.

A